Neutropenic Diet Versus Liberalized Diet in Patients With Cancer: A Systematic Review and Meta-Analysis.
This meta-analysis of 15 comparative studies involving 4,320 adults or children with cancer found no overall reduction in infection, diarrhea, or mortality with a neutropenic diet versus a liberalized diet, although an RCT-only hematologic malignancy/HSCT subgroup showed lower bacteremia/fungemia risk with the neutropenic diet.
Open original publication →What the AI sees
This meta-analysis of 15 comparative studies involving 4,320 adults or children with cancer found no overall reduction in infection, diarrhea, or mortality with a neutropenic diet versus a liberalized diet, although an RCT-only hematologic malignancy/HSCT subgroup showed lower bacteremia/fungemia risk with the neutropenic diet.
Research significance
The reported evidence suggests that routine neutropenic diets may offer no clinical advantage for short-term neutropenia or lower-risk cancer populations; as an inference, liberalized diets could reduce unnecessary dietary restriction in pediatric oncology, but pediatric-specific safety and the possible benefit of stricter diets in high-risk HSCT or prolonged neutropenia require further study.
Source abstract
PURPOSE: Neutropenic diet (ND) has historically been recommended to reduce infectious complications in patients with cancer. Although its use has declined over the past decade, recent studies, particularly in patients undergoing hematopoietic stem-cell transplantation (HSCT), have renewed concern regarding the safety of a liberalized diet (LD). We performed a meta-analysis of studies comparing ND with LD in patients with cancer. METHODS: We searched MEDLINE, Embase, and Cochrane databases from inception through January 2026. Comparative studies evaluating ND versus LD in adults or children with cancer were included. Primary outcomes were major infections and bacteremia/fungemia; secondary outcomes were pneumonia, diarrhea, and mortality. Random-effects meta-analyses were performed to calculate pooled relative risks (RRs) with 95% CIs. RESULTS: Fifteen studies including 4,320 patients met criteria for analysis. ND was not associated with significant differences in major infections (RR, 1.02 [95% CI, 0.88 to 1.18]; P = .795), bacteremia/fungemia (RR, 0.97 [95% CI, 0.78 to 1.22]; P = .805), pneumonia (RR, 0.98 [95% CI, 0.59 to 1.63]; P = .933), diarrhea (RR, 1.12 [95% CI, 0.96 to 1.31]; P = .159), or mortality (RR, 0.94 [95% CI, 0.77 to 1.15]; P = .632). Sensitivity analyses restricted to randomized controlled trials (RCTs) were consistent. In hematologic malignancy/HSCT studies (9 studies; 1,769 patients), no differences were observed across outcomes. In RCTs limited to these patients (6 studies; 855 patients), ND was associated with lower bacteremia/fungemia risk (RR, 0.67 [95% CI, 0.47 to 0.95]; P = .023), with no differences in other outcomes. CONCLUSION: ND was not associated with reductions in major infections, pneumonia, diarrhea, or mortality compared with LD. These findings do not support routine implementation of ND for patients with short-term neutropenia or lower-risk cancer populations although selected high-risk patients, particularly those undergoing HSCT or experiencing prolonged neutropenia related to hematologic malignancies, may still warrant cautious dietary practices.